Assessment of second-line antiretroviral regimens for HIV therapy in Africa.


Paton, NI; Kityo, C; Hoppe, A; Reid, A; Kambugu, A; Lugemwa, A; van Oosterhout, JJ; Kiconco, M; Siika, A; Mwebaze, R; Abwola, M; Abongomera, G; Mweemba, A; Alima, H; Atwongyeire, D; Nyirenda, R; Boles, J; Thompson, J; Tumukunde, D; Chidziva, E; Mambule, I; Arribas, JR; Easterbrook, PJ; Hakim, J; Walker, AS; Mugyenyi, P; EARNEST Trial Team, ; , COLLABORATORS; Agweng, E; Awio, P; Bakeinyaga, G; Isabirye, C; Kabuga, U; Kasuswa, S; Katuramu, M; Kityo, C; Kiweewa, F; Kyomugisha, H; Lutalo, E; Mugyenyi, P; Mulima, D; Musana, H; Musitwa, G; Musiime, V; Ndigendawan, M; Namata, H; Nkalubo, J; Ocitti Labejja, P; Okello, P; Olal, P; Pimundu, G; Segonga, P; Ssali, F; Tamale, Z; Tumukunde, D; Namala, W; Byaruhanga, R; Kayiwa, J; Tukamushaba, J; Bihabwa, G; Buluma, E; Easterbrook, P; Elbireer, A; Kambugu, A; Kamya, D; Katwere, M; Kiggundu, R; Komujuni, C; Laker, E; Lubwama, E; Mambule, I; Matovu, J; Nakajubi, A; Nakku, J; Nalumenya, R; Namuyimbwa, L; Semitala, F; Wandera, B; Wanyama, J; Mugerwa, H; Lugemwa, A; Ninsiima, E; Ssenkindu, T; Mwebe, S; Atwine, L; William, H; Katemba, C; Abunyang, S; Acaku, M; Ssebutinde, P; Kitizo, H; Kukundakwe, J; Naluguza, M; Ssegawa, K; Namayanja, ; Nsibuka, F; Tuhirirwe, P; Fortunate, M; Acen, J; Achidri, J; Amone, A; Chamai, M; Ditai, J; Kemigisa, M; Kiconco, M; Matama, C; Mbanza, D; Nambaziira, F; Owor Odoi, M; Rweyora, A; Tumwebaze, G; Kalanzi, H; Katabaazi, J; Kiyingi, A; Mbidde, M; Mugenyi, M; Mwebaze, R; Okong, P; Senoga, I; Abwola, M; Baliruno, D; Bwomezi, J; Kasede, A; Mudoola, M; Namisi, R; Ssennono, F; Tuhirwe, S; Abongomera, G; Amone, G; Abach, J; Aciro, I; Arach, B; Kidega, P; Omongin, J; Ocung, E; Odong, W; Philliam, A; Alima, H; Ahimbisibwe, B; Atuhaire, E; Atukunda, F; Bekusike, G; Bulegyeya, A; Kahatano, D; Kamukama, S; Kyoshabire, J; Nassali, A; Mbonye, A; Naturinda, TM; Ndukukire, ; Nshabohurira, A; Ntawiha, H; Rogers, A; Tibyasa, M; Kiirya, S; Atwongyeire, D; Nankya, A; Draleku, C; Nakiboneka, D; Odoch, D; Lakidi, L; Ruganda, R; Abiriga, R; Mulindwa, M; Balmoi, F; Kafuma, S; Moriku, E; Hakim, J; Reid, A; Chidziva, E; Musoro, G; Warambwa, C; Tinago, G; Mutsai, S; Phiri, M; Mudzingwa, S; Bafana, T; Masore, V; Moyo, C; Nhema, R; Chitongo, S; Heyderman, R; Kabanga, L; Kaunda, S; Kudzala, A; Lifa, L; Mallewa, J; Moore, M; Mtali, C; Musowa, G; Mwimaniwa, G; Sikwese, R; van Oosterhout, J; Ziwoya, M; Chimbaka, H; Chitete, B; Kamanga, S; Kayinga, T; Makwakwa, E; Mbiya, R; Mlenga, M; Mphande, T; Mtika, C; Mushani, G; Ndhlovu, O; Ngonga, M; Nkhana, I; Nyirenda, R; Cheruiyot, P; Kwobah, C; Lokitala Ekiru, W; Mokaya, M; Mudogo, A; Nzioka, A; Siika, A; Tanui, M; Wachira, S; Wools-Kaloustian, K; Alipalli, P; Chikatula, E; Kipaila, J; Kunda, I; Lakhi, S; Malama, J; Mufwambi, W; Mulenga, L; Mwaba, P; Mwamba, E; Mweemba, A; Namfukwe, M; Kerukadho, E; Ngwatu, B; Birungi, J; Paton, N; Boles, J; Burke, A; Castle, L; Ghuman, S; Kendall, L; Hoppe, A; Tebbs, S; Thomason, M; Thompson, J; Walker, S; Whittle, J; Wilkes, H; Young, N; Kapuya, C; Kyomuhendo, F; Kyakundi, D; Mkandawire, N; Mulambo, S; Senyonjo, S; Angus, B; Arenas-Pinto, A; Palfreeman, A; Post, F; Ishola, D; Arribas, J; Colebunders, R; Floridia, M; Giuliano, M; Mallon, P; Walsh, P; De Rosa, M; Rinaldi, E; Bertagnolio, S; Weller, I; Gilks, C; Hakim, J; Kangewende, A; Lakhi, S; Luyirika, E; Miiro, F; Mwamba, P; Mugyenyi, P; Ojoo, S; Paton, N; Phiri, S; van Oosterhout, J; Siika, A; Walker, S; Wapakabulo, A; Peto, T; French, N; Matenga, J; Cloherty, G; van Wyk, J; Norton, M; Lehrman, S; Lamba, P; Malik, K; Rooney, J; Snowden, W; Villacian, J; (2014) Assessment of second-line antiretroviral regimens for HIV therapy in Africa. The New England journal of medicine, 371 (3). pp. 234-47. ISSN 0028-4793 DOI: https://doi.org/10.1056/NEJMoa1311274

[img]
Preview
Text - Published Version
License: Copyright the publishers

Download (549kB) | Preview

Abstract

The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HIV) infection in resource-limited settings. Removing the NRTIs or replacing them with raltegravir may provide a benefit. In this open-label trial in sub-Saharan Africa, we randomly assigned 1277 adults and adolescents with HIV infection and first-line treatment failure to receive a ritonavir-boosted protease inhibitor (lopinavir-ritonavir) plus clinician-selected NRTIs (NRTI group, 426 patients), a protease inhibitor plus raltegravir in a superiority comparison (raltegravir group, 433 patients), or protease-inhibitor monotherapy after 12 weeks of induction therapy with raltegravir in a noninferiority comparison (monotherapy group, 418 patients). The primary composite end point, good HIV disease control, was defined as survival with no new World Health Organization stage 4 events, a CD4+ count of more than 250 cells per cubic millimeter, and a viral load of less than 10,000 copies per milliliter or 10,000 copies or more with no protease resistance mutations at week 96 and was analyzed with the use of imputation of data (≤4%). Good HIV disease control was achieved in 60% of the patients (mean, 255 patients) in the NRTI group, 64% of the patients (mean, 277) in the raltegravir group (P=0.21 for the comparison with the NRTI group; superiority of raltegravir not shown), and 55% of the patients (mean, 232) in the monotherapy group (noninferiority of monotherapy not shown, based on a 10-percentage-point margin). There was no significant difference in rates of grade 3 or 4 adverse events among the three groups (P=0.82). The viral load was less than 400 copies per milliliter in 86% of patients in the NRTI group, 86% in the raltegravir group (P=0.97), and 61% in the monotherapy group (P<0.001). When given with a protease inhibitor in second-line therapy, NRTIs retained substantial virologic activity without evidence of increased toxicity, and there was no advantage to replacing them with raltegravir. Virologic control was inferior with protease-inhibitor monotherapy. (Funded by European and Developing Countries Clinical Trials Partnership and others; EARNEST Current Controlled Trials number, ISRCTN37737787, and ClinicalTrials.gov number, NCT00988039.).

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
PubMed ID: 25014688
Web of Science ID: 338999800007
URI: http://researchonline.lshtm.ac.uk/id/eprint/4418940

Statistics


Download activity - last 12 months
Downloads since deposit
3Downloads
22Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item